After a PhD degree in chemistry from the Technical University of Vienna, Austria, and a postdoctoral fellowship from the California Institute of Technology, USA, Helmut held research and managerial positions in national and international pharmaceutical companies including Kwizda Pharma, Sandoz and Boehringer-Ingelheim. He joined Axentis Pharma as CEO in 2009.

Ivan has a longstanding experience in Business Development. He has been working for 30 years (until February 2009) at Ciba-Geigy and Novartis, the first seven years as laboratory head in antibiotics chemistry research, afterwards for 23 years in the Business Development & Licensing Department, where he was responsible for in and/or out-licensing of drugs in different therapeutic areas, including CNS, dermatology, inflammation, oncology, respiratory, as well as for drug delivery projects. He has negotiated and concluded numerous option and license agreements with pharmaceutical and medical device companies, more recently with companies such as Abbott Vascular, Eisai, Speedel. Ivan is a founding member of Swiss Pharma Licensing Group and was the President of the association from 2004-2008. He is currently chairman of European Pharma Licensing Council.

Allan is Professor in Pediatrics and Medical Director of the Pulmonary Function Laboratory at the Hospital for Sick Children, Toronto, Canada. He has been the pediatric representative on a task force developing standards for pulmonary function testing. Allan has conducted numerous CF clinical studies as principal investigator and, as an example, has worked already in 1998 on nebulization of liposomes containing tobramycin for the treatment of Bukholderia cepacia in patients with cystic fibrosis. He has been involved in the Colymycin Study for Parke Davies, Tobramycin 100 for Pari Pharma and many other drug development enterprises. His research interests includes aerosol research with emphasis on the delivery of medication to children with lung disease by nebulization. Clinical interests are very similar to research interest with a particular interest in the lung development following neonatal lung injury and cystic fibrosis.

Gerard is founder of Alfomec, a regulatory affairs consultancy with in depth experience of US and EU regulatory procedures and requirements. He has an established record of successful pharmaceutical and biotechnological product development with special emphasis on clinical development and manufacturing and production issues such as contract manufacture, technology transfer, process development and process validation. His professional experience includes managerial positions as International Regulatory Manager at Roche and Corporate Vice President of Regulatory Affairs at Serono. During his career, Gerard achieved 16 major product approvals in the USA and European Union and participated in more than 90 meetings with FDA and EMEA.

Christopher has a PhD in chemistry from the University of Munich and an MBA from Northwestern University Kellogg School of Management. He is a partner of New York based investment bank Brimberg, a full service broker providing a full range of services to high net worth individuals, institutional investors and corporate clients. Christopher has built a select and significant network of private and family office, venture capital and hedge fund investors dedicated to life sciences. He formerly was CFO of Nasdaq listed companies Curis and ImmunoGen.

Peter has a PhD in organic chemistry from the University of Basel and did his postdoc in Biochemistry at Purdue University, USA. He joined Ciba Geigy in 1975 and worked for the company in various leading positions in pharmaceutical development, drug delivery and in chemicals and personal care products until his retirement in 2001. Peter then founded MANDAPRO (= "Mandates and Projects"), Basel, where he is Chairman and CEO. In this function, Peter signed responsible for the re-development and registration of the liposomal product MEPACT (launched February 2010 by Takeda).

Sumio has a PhD in organic chemistry from Kyushu University, Japan. In 1972 he started as senior chemist at Yamanouchi Pharmaceuticals (now Astellas) and worked for the company in various leading positions in corporate License, International Business, Strategic Alliance. Sumio left Yamanouchi in 2001 and joined Novartis, Japan, where he has been in executive licensing positions until 2004. Since 2004, Sumio is CEO and President of Pharma Licensing Research, Inc. based in Japan. He advises Japanese pharmaceutical companies and biopharmaceutical ventures in Japan how to negotiate and collaborate with entities outside Japan, and advise entities outside Japan how to negotiate and collaborate with Japanese entities.

Renate is a specialist for pre-clinical and clinical studies. She has a graduate degree in Theoretic Mathematics from the Humboldt University, Berlin, and a postgraduate degree in Biomathematics and Informatics in Medicine from the University of Halle. She worked as Senior Director Clinical Pharmacology at Parexel and was founder and CEO of 3ClinicalResearch, Berlin. Renate worked in various executive positions in clinical development for several biotech and pharma companies in Zurich and abroad.